See the latest announcements about how Haystack is improving cancer treatment decision-making with better MRD testing.
BALTIMORE, MD, December 1, 2022 – Haystack Oncology (“Haystack”), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology to optimize
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Liquid biopsy approach delivers unparalleled sensitivity and specificity for detection of low-frequency mutant molecules to see what others can’t Financing led by Catalio Capital Management
Though early cancer diagnosis provides better outcomes for patients, many experience later disease recurrence following surgery to remove the primary tumor. This is due to
Webinar: Clinicians’ Perspectives on Circulating Tumor DNA MRD Testing in Personalizing Adjuvant Therapy for Stage II Colon Cancer
Our webinar featured on Precision Oncology News on September 22, 2022 is now available on demand. The minimal residual disease, or MRD, testing landscape shows